Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Leeds Cancer Centre, UK - Leeds Teaching Hospitals NHS Trust
Document related concepts
Transcript
Leeds Cancer Centre, UK June 2013 Leeds Cancer Centre • Provides comprehensive cancer services for • 750,000 population of Leeds • 2.7 million population of Yorkshire • Supra-regional services for 5.4 million population of YorkshireHumber Leeds Cancer Centre • Cancer services co-located at St James’s University Hospital • St James’s Institute of Oncology – clinical care / trials • Opened in 2008, £220 million development • 3rd largest cancer centre in the UK (66,000m2, 350 beds) • Leeds Institute of Molecular Medicine – laboratory research • £21M development, opened 2005 • >7,000m2 building linked to existing research laboratories St James’s Institute of Oncology • 11 floors, 12 wards, patient hotel • Excellent transport links (airport 20 minutes) • Unites • • • • • • • Non-surgical oncology (including TYA cancer) State of the art imaging and radiotherapy Specialist Cancer Surgery Haematology Clinical pathology Cancer registry Protected research beds UK cancer incidence, 2009 0 Breast Lung Colo-rectal / Anal Prostate Non-Hodgkin Lymphoma Malignant Melanoma Bladder Kidney Pancreas Leukaemia Oesophagus Uterus Stomach Ovary Oral Brain and CNS Myeloma Liver Cervix Mesothelioma Other sites 10,000 20,000 30,000 40,000 50,000 60,000 Leeds Cancer Centre • Comprehensive cancer services • • • • Surgery, chemotherapy, radiotherapy Radiology and pathology Clinical research Academic research • 24 site specific multi-disciplinary teams • • • • Common cancers - breast, colorectal, lung Intermediate cancers – gynaecology, urology, upper GI, H&N Others – liver, CNS, melanoma, skin, thyroid Haematological malignancies Multi-disciplinary teams • Site-specific teams basis of cancer care • Weekly meeting to review all new and relapsed cases • Leeds and Yorkshire • Central, specialist review of all radiology, pathology • Electronic transfer of radiology • Working towards digital pathology • Patients managed according to clinical guidelines • Guidelines agreed across Yorkshire Cancer Network • Site specific teams subject to annual peer review • Measures defined by National Cancer Action Team Our workload • 12,500 new cancer diagnoses in Yorkshire each year • 6,500 radiotherapy patients • 90,000 fractions of radiotherapy • 5,000 cycles of chemotherapy • 120 bone marrow transplants • 11,700 elective NSO admissions • 3,500 acute NSO admissions • Significant specialist surgery workload Leeds Cancer Centre • 430 consultants • Including: • 31 clinical oncologists • 24 medical oncologists • 22 haematologists • 33 histopathologists • 42 radiologists • 70+ surgeons • 35 general surgeons • 4 thoracic surgeons • 5 gynaecology surgeons • 12 urology surgeons • 4 head and neck surgeons • 8 plastic surgeons • 6 neurosurgeons • • • • 1240 nurses 100 radiographers 60 medical physicists 20 allied health professionals • Includes • dieticians • occupational therapists • physiotherapists • speech and Language therapists • social workers Cancer surgery • First class Service Delivery incorporating state of the art technologies Laparoscopic Surgery Robotic Surgery Chemotherapy • Comprehensive range of chemotherapy services • Intravenous / Oral • Intra-peritoneal / Intra-vesical / Intra-arterial • Rapid access to modern drugs • Modern cytoxic chemotherapy drugs • Targeted therapies New agents targeting the VEGF Pathway Antibodies inhibiting VEGF receptors Soluble VEGF receptors (VEGF-TRAP) Antibodies inhibiting VEGF (e.g. bevacizumab) VEGF VEGFR1 FLT1 VEGFR2 KDR P– P– –P –P Permeability Small-molecules inhibiting VEGF receptors (TKIs) (e.g. PTK-787) P– P– Cation channel –P –P P– P– Migration, permeability, DNA synthesis, survival Ribozymes (Angiozyme) Angiogenesis Lymphangiogenesis –P –P Radiotherapy • Linear accelerators • 10 NHS, 2 research • 4 Planning CTs • Brachytherapy unit • State of the art technology • • • • Image guided radiotherapy Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy Stereotactic radiosurgery unit • UK lead in stereotactic body radiation • World first clinical use of Agility (beam shaping device) and use with SABR technique – October 2012 Haematology • Supra-regional service (3.8 million) • Treats both adults and TYA • 43 beds, +ve pressure hepa-filtered • Bone marrow transplantation • 50 allografts, 55 autografts • On-site stem cell harvest • National lead for PNH • Prof Peter Hillmen • Strong research record • Myeloid – Dr David Bowen • Lymphoid – Prof Pete Hillmen • Myeloma – Prof Gordon Cook Paediatric and adolescent cancer • Designated treatment centre for 3.8 million population • • • • Paediatric oncology Paediatric haematology Teenage and Young Adult Bone marrow and stem cell transplantation • Services located at Leeds General Infirmary • 3 in-patient wards, 25 beds • Dedicated day care unit and out-patient clinic • One of the most active research centres in UK • National leadership roles throughout • International leadership in TYA and cancer survivorship Clinical Informatics • PPM • All cancer diagnoses since 1990 • ChemoRx and RadioRx since 1995 • All clinic letters, MDT reviews since 2002 • Clinical outcomes • Early morbidity/mortality • Overall survival • Open-source EHR in development • Trust-wide clinical portal • Links to primary care • SystmOne and EMIS Pathology • Standard light microscopy plus antibodies • Molecular phenotyping • HER2 over-expression in breast cancer • EGFR mutations in lung cancer • K-Ras mutations in colorectal cancer • Part of CR-UK Stratified Medicine Programme • Aiming to deliver Next Generation Sequencing • Cancer Genome in 4 hrs for $1000 Clinical trials - Recruitment • Strong clinical trial recruitment across LTHT • 33% of all patients recruited to trials • 10% of patients recruited to randomised controlled trials • Large, dedicated trial support team • Nurses, co-ordinators, data clerks, administrative/finance • Leadership profile • Colorectal cancer; ovarian cancer; breast cancer Clinical trials - Leadership • Chief Investigator on large international phase III trials • • • • ICON3 – Dr Tim Perren, NEJM, 2011 FOCUS2 – Prof Matt Seymour, Lancet, 2011 EMBRACE – Prof Chris Twelves, Lancet 2011 CR07 – Prof Sebag-Montefiore, Lancet 2009 • Leeds Clinical Trials Unit • Prof Julia Brown • Co-ordinating centre for phase 1 Myeloma UK Network • NCRN – national co-ordinating centre for cancer research • Prof Matt Seymour Cancer Research UK Clinical Centre • Director – Prof Tim Bishop • Formal partnership between • University of Leeds, LTHT, Cancer Research UK • 4 core programmes • • • • Genetics and epigenetics of cancer Targeted therapies Early phase and randomised prospective clinical trials Biomarkers and pathology • Aims to harness the scientific power of Leeds-based cancer researchers in order to deliver improvements in cancer therapy at local, national and international level. Leeds Institute of Molecular Medicine • Director Prof Peter Selby • Level 9 - Genetics; Molecular Gastroenterology • Level 8 - Neurosciences • Level 7 - Experimental Cancer Therapeutics • Level 6 - Experimental Haematology • Level 5 - Targeted Cancer Therapies • Level 4 - Cancer Pathology, Tumour Biology • Level 3 - Support services Radiation research • Prof David Sebag-Montefiore • Dedicated research facility • Collaboration with Elekta • UK consortium with Elekta • Christie, Manchester • Marsden, Sutton • International consortium • Netherlands Cancer Institute • Princess Margaret (Toronto) • Algemeines Krankenhaus (Vienna) Imaging Research • Leadership in both PET and MRI • Dr Andrew Scarsbrook Prof David Buckley • Involvement with CR-UK • Large portfolio of oncology projects (>150) • Dedicated research PET/CT machine Surgical research • Led by Prof David Jayne INTRA-ABDOMINAL PLATFORMS TISSUE-DEVICE INTERACTIONS INTRACORPOREAL ROBOTICS Surgical Technologies BIOSENSORS Stratified Surgery FLUORESCENCE-GUIDED SURGERY Surgical research MRC/EME/NIHR ROLARR Trial • Robotic vs Laparoscopic Rectal Cancer • £1.2m over 5 years • Pan-World randomised control trial Intraoperative fluorescence for Stratified colon cancer surgery MRC/EME/NINR GLiSten Trial • £1m over 3 years • Multicentre UK randomised controlled trial • Fluorescence guided surgery Any questions ?
